← Human Trials & Peer-Reviewed Studies
Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy
Plain-language guide to PMID 11440277 (2001): placebo-controlled randomized controlled trial study of Octreotide, diabetic retinopathy and glaucoma.
Key Facts
- PMID
- 11440277
- Journal
- Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
- Year
- 2001
- Study type
- Randomized Controlled Trial
- Authors
- Boehm BO et al. (5 authors)
- DOI
- 10.1055/s-2001-15282
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide in the context of diabetic retinopathy and glaucoma in this randomized controlled trial publication.
Growth hormone and insulin-like growth factor-I have been implicated as strong promoters of proliferative diabetic retinopathy.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Reading ophthalmologists were masked for octreotide use, diabetologists were aware of that treatment.
Nine patients received 100 microg tid octreotide (verum) subcutaneously for a maximum of 36 months.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.
Randomized trial in a University hospital setting.
Nine diabetics served as controls, no placebo treatment was used.
Episodes of vitreous hemorrhages were counted, measurement of visual acuity, estimation of neovascularization by stereoscopic fundus photography and fluorescein angiography were carried out.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Diabetic Retinopathy, Hormones, Neovascularization, Pathologic, Octreotide and Ophthalmologic Surgical Procedures.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Octreotide in people with diabetic retinopathy and glaucoma.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2001 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.
More context: the Octreotide compound page, Diabetic retinopathy and glaucoma research.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.